Patients with RA Benefit from Peresolimab.

Published Date: 20 May 2023

After 12 weeks, the DAS28-CRP, which is based on the C-reactive protein level, changed significantly more in patients taking peresolimab 700 mg compared to placebo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot